Minute Insight: Trials Sponsored By Medtronic and Biosense Webster Show Benefits Of AFib Ablation
Results from two industry-supported clinical trials published in the last week offer more support for treating atrial fibrillation with catheter ablation rather than medication alone.
You may also be interested in...
FDA Clears iRhythm’s Afib-Detecting Wearable Running Software Co-Developed By Verily
The ZEUS (Zio ECG Utilization Software) system for iRhythm’s Zio Watch detects and characterizes atrial fibrillation over time to aid doctors in diagnosing the condition. The company expects to begin commercializing it next year.
Exec Chat: Biosense Webster Is Ready For Next Chapters Of The Electrophysiology Story
Medtech Insight talked to Michael Bodner, the worldwide president of Johnson & Johnson/Biosense Webster, about the company’s plans to stay number one in the cardiac ablation market. In part 1 of the interview, the medtech veteran talked about the company's plan to compete in the crowded pulsed field ablation field.
FDA Approves Medtronic’s Arctic Front For ‘First-Line’ Treatment For AFib
The new approval allows Medtronic to promote cryoablation as the first option for patients with recurrent symptomatic paroxysmal atrial fibrillation. Previously, it was only approved for patients who had already tried to manage their atrial fibrillation with drugs.